NCT01501266已完成不适用
Faslodex Specific Clinical Experience Investigation for Long-term Use
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 660
- 试验地点
- 1
- 主要终点
- Incidence of serious adverse events.
研究概览
简要总结
The purpose of this study is to confirm the safety profile such as the frequency of serious adverse events or any unexpected adverse events and overall efficacy of Faslodex for long term treatment in daily clinical practice.
详细描述
MC MD
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Patients treated with Faslodex for the first time due to postmenopausal breast cancer
排除标准
- 未提供
结局指标
主要结局
Incidence of serious adverse events.
时间窗: 1 Year
Incidence of adverse drug reactions.
时间窗: 1 year
次要结局
- Incidence of adverse drug reactions with injection site reaction, thromboembolic events and hepatic impairment(1 year)
- Progression-free survival(1 year)
研究者
研究点 (1)
Loading locations...
相似试验
终止
不适用
Faslodex Observations During Regular Use by Advanced Mammacarcinoma PatientsBreast CancerNCT00241462AstraZeneca150
已完成
不适用
Observational Usage Study of Faslodex in Patients Suffering From Initial Breast Cancer in FranceBreast CancerNCT00681369AstraZeneca217
进行中（未招募）
不适用
Clinical study for the assessment of safety and efficacy of Bezafibrate as a drug therapy for patients suffering from an inborn muscular dysfunction characterized by intramuscular lack of energy supplymitochondrial disorderEUCTR2012-002692-34-ATniv.-Klinik für Kinder- und Jugendheilkunde16
已完成
不适用
Retrospective Study Assessment Treatment Response Faslodex®( 500 mg)Malignant Neoplasm of Breast Stage IVNCT01509625Isabel Blancas272
招募中
不适用
Resuscitative TEE Collaborative RegistryCardiac Arrest CirculatoryCardiac Arrest, Out-Of-HospitalShockHemodynamic InstabilityCardiac ArrestNCT04972526University of Pennsylvania1,000